Aegis Special Situations QP Fund LLC - Series Medtech VI
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$828K
Investors
13
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Aegis Special Situations QP Fund LLC - Series Medtech VI is a Delaware limited liability company that filed a Form D with the SEC on February 9, 2024, describing itself as a private equity fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers equity and pooled investment fund interests. Aegis Special Situations QP Fund LLC - Series Medtech VI reported $827,750 sold from 13 investors of a $5,500,000 total offering as of the Form D filed February 9, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Aegis Capital Corp. (CRD 15007), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $20,693 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 810 Seventh Avenue, 18th Floor, New York, NY 10019.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Feb 9, 2024
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
3
lapsed
Latest event New filer · Feb 9, 2024
SEC.govFund family Part of the Aegis Special Situations QP Fund Series Medtech family: 4 vehicles across 4 generations · adviser of record Aegis Capital Corp. · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 filing event with values and deltas, latest 2024-02-09, and alerts on the next one
- 3 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 15007 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a private equity fund
Auditor named on Form ADV: Citrin Cooperman & Company, LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2024-02-09: 1 related person added and 0 removed against the filing of 2023-01-12; 5 now listed. The names are in the Terminal feed.
Cosme Ordonez
Executive Officer, Director · New York, NY
Manager of the Manager and Senior Managing Director of Investment Banking, Private Equity of the Investment Advisor
Adam Stern
Executive Officer, Director · New York, NY
Manager of the Manager and Head of Private Equity Banking of the Investment Advisor
Aegis Special Situations Management LLC
Director · New York, NY
Manager of the Issuer
Aegis Capital Corp.
Promoter · New York, NY
Investment Advisor of the Issuer
Aegis Capital Holding Corp.
Promoter · New York, NY
Sole Member of the Manager and principal stockholder of the Investment Advisor
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Aegis Capital Corp.CRD 15007 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states and outside the United States
Questions About Aegis Special Situations QP Fund LLC - Series Medtech VI
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Aegis Special Situations QP Fund LLC - Series Medtech VI?
Aegis Special Situations QP Fund LLC - Series Medtech VI is a Delaware limited liability company that filed a Form D with the SEC on February 9, 2024 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of equity and pooled investment fund interests.
Is Aegis Special Situations QP Fund LLC - Series Medtech VI legit?
AltStreet does not rate legitimacy; it reports the public record. Aegis Special Situations QP Fund LLC - Series Medtech VI filed a Form D with the SEC on February 9, 2024 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $827,750 sold to 13 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Aegis Special Situations QP Fund LLC - Series Medtech VI registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Aegis Special Situations QP Fund LLC - Series Medtech VI claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Aegis Special Situations QP Fund LLC - Series Medtech VI raised?
Aegis Special Situations QP Fund LLC - Series Medtech VI reported $827,750 sold from 13 investors of a $5,500,000 total offering as of the Form D filed February 9, 2024.
Who can invest in Aegis Special Situations QP Fund LLC - Series Medtech VI?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Aegis Special Situations QP Fund LLC - Series Medtech VI?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Aegis Special Situations QP Fund LLC - Series Medtech VI and how are they paid?
The Form D names Aegis Capital Corp. (CRD 15007), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $20,693 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Aegis Special Situations QP Fund LLC - Series Medtech VI?
The Form D lists 5 related persons: Cosme Ordonez, executive officer, director (Manager of the Manager and Senior Managing Director of Investment Banking, Private Equity of the Investment Advisor); Adam Stern, executive officer, director (Manager of the Manager and Head of Private Equity Banking of the Investment Advisor); Aegis Special Situations Management LLC, director (Manager of the Issuer); Aegis Capital Corp., promoter (Investment Advisor of the Issuer); Aegis Capital Holding Corp., promoter (Sole Member of the Manager and principal stockholder of the Investment Advisor). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Aegis Special Situations QP Fund LLC - Series Medtech VI located?
The issuer's address on its SEC filings is 810 Seventh Avenue, 18th Floor, New York, NY 10019. Its phone number of record is 6465573481. It is organized under the laws of Delaware.
How long is the Aegis Special Situations QP Fund LLC - Series Medtech VI offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Aegis Special Situations QP Fund LLC - Series Medtech VI?
The Form D reports a revenue range of No Revenues.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.